Content
06/03/2024 San Francisco, CA USA
Valar Labs completed $22 million Series A Round funding. Investors include Pear VC, DCVC.
#Biotech  
About
Valar Labs is a precision medicine company developing computational histology AI tests for predicting response to cancer therapies. Our goal is to provide every patient and physician the ability to select the best treatment based on the patient's tumor biology. Our bladder cancer test, Vesta, predicts which patients are unlikely to benefit from BCG therapy and provides detailed risk stratification for recurrence and progression.
Startup
Valar Labs
https://www.valarlabs.com Claim Profile
Location:
San Francisco, CA USA
Sector:
Biotech
Download StockFan App Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.